Revive Therapeutics INC.

pharmaceutical and therapeutics manufacturer

🤖

AI Overview

With $115K in lobbying spend across 11 quarterly filings, Revive Therapeutics INC is an active lobbying client. Their lobbying covers 1 issue area. Active from 2021 to 2023.

$115K
Total Spend
3
Years Active
1
Firms Hired
1
Lobbyists Deployed
1
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2021$90K
2022$25K
2023$0

Issues Lobbied

Lobbying Firms

Lobbyists

Government Agencies Targeted

These are the government entities that Revive Therapeutics INC. disclosed contacting in their lobbying filings.

Natl Institutes of Health (NIH)SENATEHealth & Human Services, Dept of (HHS)HOUSE OF REPRESENTATIVES
View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues

Advocating for acceleration and approval of bucillamine as a COVID-19 critical therapeutic solution. In addition, advocating for TBI, PTSD applications of other medicines in development.

Advocating for assistance w/Phase 3 trial for Bucillamine

Advocating for assistance w/Phase 3 trial for Bucillamine, educating Members of Congress, BARDA/HHS and NIH regarding Bucillamine as a repurposed drug for COVID19.

Related Analysis

Related Investigations

Similar Clients

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.